Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% is a parenteral nutrition solution providing amino acids, dextrose, and electrolytes. The amino acids serve as substrates for protein synthesis; dextrose supplies caloric energy; electrolytes maintain acid-base balance and osmotic equilibrium.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis; electrolytes maintain acid-base balance and cellular function; dextrose provides caloric energy. Sulfite-free formulation reduces risk of allergic reactions.
FDA-approved: Parenteral nutrition for patients requiring intravenous nutritional support when oral or enteral nutrition is inadequate or not possible.,Off-label: Adjunctive therapy in catabolic states, burns, trauma.
Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition,Peripheral or central intravenous alimentation
Intravenous infusion: 1-2 L/day as total parenteral nutrition; typical rate 100-125 m L/hour based on caloric and nitrogen needs.
Intravenous infusion; dose determined by individual protein and caloric requirements, typically 1.5 to 2.5 g/kg/day of amino acids (equivalent to 35-59 m L/kg/day of TRAVASOL 4.25%) for adults.
Not applicable as a single agent; components have varying half-lives: dextrose ~2 h (glucose), amino acids ~1-3 h (plasma clearance), electrolytes proportional to renal function
Amino acids: 0.5-2 hours; dextrose: 1-2 hours; clinical context: rapid elimination necessitates continuous infusion to maintain nutrient levels.
Contraindicated in severe renal impairment (Cr Cl <25 m L/min) without CRRT; for Cr Cl 25-50 m L/min reduce volume by 50% and monitor electrolytes; Cr Cl >50 m L/min no adjustment.
In patients with GFR <50 m L/min: reduce amino acid dose to 0.6-1.0 g/kg/day; monitor BUN and electrolyte levels; avoid in severe renal impairment unless on renal replacement therapy.
Amino acids, dextrose, and electrolytes in parenteral nutrition are not directly teratogenic. However, the solution is used for maternal nutritional support; no human data on direct fetal risks. Use only if clearly needed. No known structural teratogenicity; potential for metabolic disturbances if maternal homeostasis not maintained.
No teratogenic effects reported in humans. Travasol (amino acids) and dextrose are essential nutrients; no fetal risk is anticipated when used appropriately. No specific trimester risks identified.
TRAVASOL 4.25% with dextrose 15% is a hypertonic parenteral nutrition solution; must be administered via central venous catheter. Monitor serum electrolytes, glucose, and liver function tests. Adjust rate to avoid hyperglycemia or hypoglycemia. Contains no sulfite, suitable for sulfite-sensitive patients. Check for incompatibilities with other IV additives.
Contains 4.25% amino acids and 20% dextrose, providing approximately 0.96 kcal/m L. Not for peripheral administration due to high osmolarity (~2000 m Osm/L). Must be administered via central line. Contains no sulfite; safe for sulfite-allergic patients. Electrolytes included; monitor serum electrolyte levels. Do not use if solution is cloudy or precipitate present.
No interactions on record
No interactions on record
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER and TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER are distinct pharmacological agents. TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER belongs to the Parenteral Nutrition Solution class and is primarily used for FDA-approved: Parenteral nutrition for patients requiring intravenous nutritional support when oral or enteral nutrition is inadequate or not possible.Off-label: Adjunctive therapy in catabolic states, burns, trauma.. TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER belongs to the Parenteral Nutrition Solution class and is primarily used for Parenteral nutrition in patients unable to receive adequate oral or enteral nutritionPeripheral or central intravenous alimentation. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER carries a safety status of Category C, whereas TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the Krebs cycle; electrolytes are excreted or reabsorbed by renal mechanisms.
Amino acids are metabolized via transamination and deamination pathways; dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are not metabolized but are eliminated via renal excretion.
Renal: 100% (primarily as free water and electrolytes; dextrose is metabolized; amino acids are deaminated and urea is excreted renally)
Renal excretion of amino acids and dextrose metabolites; virtually 100% renal elimination of infused water and electrolytes.
Negligible for most components; amino acids: <20% (primarily albumin); dextrose: none; electrolytes: variable, e.g., calcium ~50% (albumin), magnesium ~30% (albumin)
Amino acids: minimal (<10%); dextrose: negligible; no significant binding.
Not applicable as a mixture; approximate Vd for dextrose = 0.2 L/kg (extracellular fluid); electrolytes distribute in total body water (~0.6 L/kg for sodium, ~0.5 L/kg for chloride); amino acids Vd ~0.3-0.5 L/kg
Amino acids: 0.3-0.5 L/kg; dextrose: 0.2 L/kg; reflects distribution in total body water.
I. V. only: 100%
Intravenous: 100%; not administered via enteral routes.
Child-Pugh A: no adjustment; Child-Pugh B: reduce amino acid dose by 50% and monitor ammonia; Child-Pugh C: contraindicated due to risk of encephalopathy.
In Child-Pugh B or C: avoid use due to risk of hepatic encephalopathy from amino acid load; use specialized hepatic formulations if necessary.
Starting dose: 0.5-1 g amino acids/kg/day, titrated up to 2-3 g/kg/day based on weight; typical volume 100-150 m L/kg/day for infants; adjust dextrose to maintain euglycemia.
Dose based on protein and caloric needs: infants and children typically 2.0-3.0 g/kg/day of amino acids (equivalent to 47-71 m L/kg/day of TRAVASOL 4.25%); adjust for age and clinical condition.
Start at lower end of dosing range (e.g., 0.5-1 L/day) with slower infusion rate (e.g., 50-75 m L/hour) due to decreased renal clearance; monitor glucose and electrolytes closely.
No specific dosage adjustment except based on renal and hepatic function; monitor fluid and electrolyte balance closely due to decreased physiological reserve and higher risk of volume overload.
Contains sulfites which may cause allergic-type reactions including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible individuals. Sulfite sensitivity is more common in asthmatics.
None
No direct food interactions, but patients may require adjustments to oral intake during parenteral nutrition transition. Avoid grapefruit juice if certain medications are co-administered (e.g., cyclosporine).
No oral food interactions as this is parenteral nutrition. However, if patient is also eating, manage total caloric and electrolyte intake. Avoid grapefruit products (affects CYP450 metabolism of some additives).
Excretion into breast milk of components is minimal; no specific M/P ratio reported. Considered compatible with breastfeeding if maternal nutritional status is adequate. Monitor infant for metabolic or electrolyte disturbances only if maternal therapy prolonged.
Amino acids and dextrose are normal constituents of breast milk. No adverse effects expected. M/P ratio not established; considered compatible with breastfeeding.
No specific pregnancy pharmacokinetic data. Use standard dosing adjusted for maternal weight and metabolic demands. Monitor glucose tolerance; pregnancy may require increased insulin or reduced dextrose load. Electrolyte needs may increase due to expanded plasma volume; adjust accordingly.
No specific dose adjustments required. Pregnancy may alter fluid and electrolyte needs; adjust based on maternal weight and clinical status. Monitor glucose tolerance due to dextrose load; consider insulin if hyperglycemia develops.
This medication is a form of nutrition given through a vein when you cannot eat.,Your blood sugar and electrolytes will be monitored regularly.,Report any signs of infection (redness, swelling, pain) at the catheter site.,Do not adjust the infusion rate yourself; it is controlled by healthcare staff.,Inform your healthcare provider about all other medications you are taking.
This medication provides nutrition through a central vein.,Report any signs of infection at the catheter site (redness, swelling, pain, fever).,Do not stop the infusion without medical guidance.,Monitor for symptoms of high blood sugar (excessive thirst, frequent urination).,Keep all follow-up appointments for blood tests.